

False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria?

M. Farhat,** C. Greenaway,** M. Pai,*§ D. Menzies*

* Respiratory Epidemiology and Clinical Research Unit, Montreal Chest Institute, McGill University, Montreal, Quebec, Canada; † Massachusetts General Hospital, Harvard University, Boston, Massachusetts, USA; ‡ Division of Infectious Disease and Microbiology, SMBD-Jewish General Hospital, McGill University, Montreal, § Joint Departments of Epidemiology & Biostatistics and Occupational Health, McGill University, Montreal, Quebec, Canada

SUMMARY

BACKGROUND: Despite certain drawbacks, the tuberculin skin test (TST) remains in widespread use. Important advantages of the TST are its low cost, simplicity and interpretation based on extensive published literature. However, TST specificity is reduced by bacille Calmette-Guérin (BCG) vaccination and exposure to non-tuberculous mycobacteria (NTM).

METHODS: To estimate TST specificity, we reviewed the published literature since 1966 regarding the effect of BCG vaccination and NTM infection on TST. Studies selected included healthy subjects with documented BCG vaccination status, including age at vaccination. Studies of NTM effect had used standardised NTM antigens in healthy subjects.

RESULTS: In 24 studies involving 240 203 subjects BCG-vaccinated as infants, 20 406 (8.5%) had a TST of 10+ mm attributable to BCG, but only 56/5639 (1%) were TST-positive if tested ≥ 10 years after BCG. In 12 studies

of 12 728 subjects vaccinated after their first birthday, 5314 (41.8%) had a false-positive TST of 10+ mm, and 191/898 (21.2%) after 10 years. Type of tuberculin test did not modify these results. In 18 studies involving 1 169 105 subjects, the absolute prevalence of false-positive TST from NTM cross-reactivity ranged from 0.1% to 2.3% in different regions.

CONCLUSIONS: The effect on TST of BCG received in infancy is minimal, especially ≥ 10 years after vaccination. BCG received after infancy produces more frequent, more persistent and larger TST reactions. NTM is not a clinically important cause of false-positive TST, except in populations with a high prevalence of NTM sensitisation and a very low prevalence of TB infection.

KEY WORDS: tuberculin skin test; latent TB infection; atypical mycobacteria; environmental mycobacteria; non-tuberculous mycobacteria; BCG vaccination

DESPITE CERTAIN DRAWBACKS, the tuberculin skin test (TST) remains in widespread use. The test is inexpensive and simple, facilitating its use in the field and in resource-limited settings. A very important advantage of the TST is the extensive published evidence from numerous cross-sectional and longitudinal studies in different settings and populations. This permits estimation of the likelihood of false-positive and false-negative tests, as well as risk of progression to active disease. However, accurate interpretation of the TST depends upon careful synthesis of this vast evidence, a difficult challenge for most busy clinicians.

New interferon-gamma release assays (IGRA) such as the QuantiFERON-TB Gold (Cellestis, Carnegie, VIC, Australia) and T-SPOT.TB tests, provide attractive alternatives to the TST. These tests are not affected by bacille Calmette-Guérin (BCG) vaccination nor by certain non-tuberculous mycobacteria (NTM), and so should be more specific than the TST.¹ However, their

higher cost and requirement for laboratory facilities may limit their adoption. Thus it seems timely to re-evaluate the situations and populations most likely to have false-positive TST reactions, for whom the new IGRA may be more accurate.

We conducted an extensive literature review and meta-analysis to determine the best possible estimates of false-positive TST reactions related to the two most important causes: prior BCG vaccination and exposure to NTM. We also examined factors modifying the effect of BCG vaccination on TST.

METHODS

Literature search

A Medline search was conducted for articles published between 1966 and 2005 using the terms 'tuberculosis', 'atypical mycobacteria', 'atypical mycobacterial infections', 'environmental mycobacteria',

Correspondence to: Dr Dick Menzies, Montreal Chest Institute, 3650 St-Urbain, Rm K1.24, Montreal, QC H2X 2P4, Canada. Tel: (+1) 514-934-1934, ext 32128/32129. Fax: (+1) 514-843-2083. e-mail: dick.menzies@mcgill.ca

Article submitted 10 March 2006. Final version accepted 26 June 2006.

'non-tuberculous mycobacteria', 'BCG vaccination', and 'skin tests' or 'tuberculin skin tests'. The search was limited to human studies published in the English language. Titles and abstracts of all original articles found were reviewed. If the abstract suggested that the study might meet the review inclusion criteria (see below), the full article was reviewed. The reference lists from these articles, and related reviews, were used to identify further original articles. We contacted the authors of some studies for additional data. Reviewers suggested two additional studies.

Study selection

To be included in the analysis of the effect of BCG vaccination on TST results, studies must have performed tuberculin testing using the Mantoux technique and standardised tuberculin antigens in healthy populations, some of whom had been BCG vaccinated and others who had not (controls). Furthermore, BCG vaccination must have been documented by vaccination records or presence of scar. Age at BCG vaccination had to be known, as age of vaccination and the interval between vaccination and TST are recognised determinants of the effect of BCG on tuberculin reactions.²⁻⁷ The minimum interval between BCG vaccination and TST had to be 1 year, and the type of tuberculin test material had to be specified, as this has been identified as a potential determinant.⁸ A total of 400 articles were initially identified; of these, 65 were selected for full review and 31 met the criteria for inclusion

for estimate of BCG effect (summarised in Tables 1 and 2).

A number of studies cited in an earlier meta-analysis on this topic⁸ were not included in our estimate of effect for the following reasons: BCG was ascertained by history in all or a substantial proportion of subjects,³⁶⁻⁴⁰ age of vaccination was not known or not reported,³⁶⁻⁴⁶ interval was not known or not reported and the interval between TST and BCG was less than 1 year in some of the subjects.^{4,47-49} The booster phenomenon was included as a positive TST;^{42,43,49} the actual numbers with specific TST reaction sizes were not given,⁵⁰ there were very few⁵¹ or no non-vaccinated controls.^{4,48,50} Others were not used because repeat vaccination at an older age was given to an unknown number who had been tuberculin-negative.^{5,51-53} In the last of these studies,⁵ the sub-group that had been vaccinated only in infancy was included.

To be included in the estimate of NTM effect, studies must have: tested healthy populations who were not BCG-vaccinated (or the authors adjusted for BCG), using purified NTM antigens from one of five recognised centres—the US Public Health Service (Atlanta, GA, USA), Statens Serum Institut (Copenhagen, Denmark), Connaught Laboratories (Toronto, Canada), Weybridge Laboratory (London, UK), or the laboratory of Dr Stanford (Royal Free & University College Medical School, London, UK). Studies testing patients with active mycobacterial disease were excluded. A total of 147 studies were identified from the literature

Table 1 Summary of methodology of studies in healthy populations that had received BCG in infancy (up to 1 year old)

Author, year	Setting	BCG vaccine type/source	Methods of verification	TST method*	Age when TST, years	TST in BCG, n tested	TST in non-vaccinated, n tested
Eason, 1987 ⁹	Solomon Island	Unspecified	Scar/records	5 TU PPD-S	1-8	1425	357
Karalliedde, 1987 ¹⁰	Sri Lanka	Japan. UNICEF	Scar	1 TU RT-23	5-11	522	None [†]
al-Kassimi, 1991 ¹¹	Saudi Arabia	Many strains were used	Scar	5 TU PPD-S	5-13	1945	643
el-Kassimi, 1991 ¹²	Saudi Arabia	Many strains were used	Scar	5 TU PPD-S	5-14	283	44
Menzies, 1992 ⁶	Montreal	Armand Frappier	Records	5 TU PPD-S	11-17	1041	3 118
Young, 1992 ¹³	North Ontario	Connaught (Toronto)	Records	5 TU PPD-S	1-15	522	126
al-Kassimi, 1993 ¹⁴	Saudi Arabia	Many strains were used	Scar	5 TU PPD-S	5-14	2 119	681
Menzies, 1994 ⁷	Montreal	Armand Frappier	Records	5 TU PPD-S	21	381	951
Miret-Cuadras, 1996 ⁵	Spain	Danish	Scar	5 TU RT-23	20-25	446	887
Bener, 1996 ¹⁵	Arab Emirates	Unspecified	Scar	5 TU PPD-S	5-15	544	238
Getchell, 1992 ¹⁶	Peru	Unspecified	Scar	5 TU PPD-S	5-25+	251	40
Liard, 1996 ¹⁷	Algeria	Unspecified	Scar	2 TU RT-23	5-18	920	315
Schwartzman, 1996 ¹⁸	Montreal	Armand Frappier	Records	5 TU PPD-S	36	76	133
Jochem, 1997 ¹⁹	Montreal	Armand Frappier	Records	5 TU PPD-S	39	11	52
Bosman, 1998 ²⁰	Kenya	Unspecified	Scar	2 TU RT-23	6-13	25 381	14 984
Chadha, 2000 ²¹	India	Danish 1331	Scar	1 TU RT-23	5-9	3 165 [‡]	2 861 [§]
Chadha, 2001 ²²	India	Danish 1331	Scar	1 TU RT-23	6-7	5 653	3 687 [§]
Tanzania TB Survey, 2001 ²³	Tanzania	Unspecified	Scar	2 TU RT-23	6-14	161 357	84 599
Chadha, 2003 ²⁴	India	Danish 1331	Scar	1 TU RT-23	5-9	5 542	2 991 [§]
Bierrenbach, 2003 ²⁵	Brazil	Moreau	Scar	2 TU RT-23	7-14	437	633
Lienhardt, 2003 ²⁶	The Gambia	Unspecified	Scar	2 TU RT-23	1-50+	2 314	2 691 [§]
Chadha, 2004 ²⁷	India	Danish 1331	Scar	1 TU RT-23	5-9	24 398	31 476
Hill, 2004 ²⁸	The Gambia	Unspecified	Scar	2 TU RT-23	20	959	985 [§]
Pai, 2005 ²⁹	India	Danish 1331	Scar	1 TU RT-23	22	511	200 [§]

* Positive TST = ≥ 10 mm unless otherwise stated. PPD-S = studies using commercial PPD standardised to PPD-S.

[†] Substantial confounding with age. BCG coverage higher in older children.

[‡] Prevalence of LTBI estimated from smear-positive TB incidence (see text).

[§] Published information supplemented by data from authors.

BCG = bacille Calmette-Guérin; TST = tuberculin skin test; LTBI = latent tuberculosis infection; TB = tuberculosis; PPD = purified protein derivative.

Table 2 Summary of methodology of studies in healthy populations that had received BCG after the age of 1 year

Author, year	Setting	BCG vaccine type	Methods of verification	TST method [†]	Age at BCG, years	Age at TST, years	Interval BCG-TST, years	BCG-vaccinated <i>n</i> tested	Non-vaccinated <i>n</i> tested
Abrahams, 1967 ^{30*}	Australia	Danish	Records	5 TU PPD-S	8-12	13-14	1-5	53	1012
Abrahams, 1968 ^{31*}	Australia	Danish	Records	5 TU PPD-S	8-12	13	1-5	395	374
Comstock, 1971 ³²	Southern US	Chicago	Records	5 TU PPD-S	5-12	5-12	8-15	63	66
Horwitz, 1972 ³³	Copenhagen	All types	Study	2 TU RT-23	7	12	5	716	None*
Baily, 1980 ³⁴	India	Pasteur, Danish	Records	3 TU PPD-S	5-14	9-18	4	8702	8698 [‡]
Eason, 1987 ⁹	Solomon Islands	Not specified	Records	5 TU PPD-S	0 and 7	10-19	3-12	1395	80
Menzies, 1992 ⁶	Montreal	Armand Frappier	Records	5 TU PPD-S	6-8	6-8	7-19	469	3118
Menzies, 1994 ⁷	Montreal	Armand Frappier	Records	5 TU PPD-S	2-10		10-25	210	951
Ildirim, 1995 ³	Turkey	Danish, Pasteur	Records	5 TU PPD-S	0 and 5	6-12	1-6	470	1518 [§]
Schwartzman, 1996 ¹⁸	Montreal	Armand Frappier	Records	5 TU PPD-S	>2	36	20-30	117	133
Jochem, 1997 ¹⁹	Montreal	Armand Frappier	Records	5 TU PPD-S	>2	38.7	20-30	39	52
Kang, 2005 ³⁵	South Korea	Pasteur	Scar	2 TU RT-23	0 and 12	20	8	99	None*

* Prevalence of LTBI in non-vaccinated estimated from smear-positive TB incidence (see text).

[†] Positive TST = 10+ mm unless otherwise stated. PPD-S = studies using commercial PPD standardised to PPD-S.

[‡] In this substudy of the Madras BCG trial (see page 60-61 of reference³⁴) all participants were TST-negative before vaccination and BCG vaccinees as well as the placebo group were retested after 4 years.

[§] Ildirim—two or three scars were interpreted to mean that the child must have received vaccination at least once at the age of 5-6 years.

BCG = bacille Calmette-Guérin; TST = tuberculin skin test; LTBI = latent tuberculosis infection; PPD = purified protein derivative.

Table 3 Summary of methodology of 18 studies measuring prevalence of NTM sensitivity in healthy populations

Author, year	Setting	Participants		TST methods	NTM antigens	
		Age, years range or mean	<i>n</i>		Types	Source
Bleiker, 1968 ⁵⁴	The Netherlands	6-15	3 108	2 TU RT-23	2 U PPD-avian	Weybridge, England
	France	6-15	2 038			SSI, Copenhagen
Jeanes, 1969 ⁵⁵	Canada	14-22	26 158	5 TU PPD-S	PPDG, B	US Department of Health
			7 583			
Edwards, 1973 ⁵⁶	US-North*	17-21	573 141	5 TU PPD-S	PPDB, G	US Department of Health
	US-Central [†]	17-21	268 554			
	US-South [‡]	17-21	185 475			
Brickman, 1974 ⁵⁷	Montreal	4-6	567	5 TU PPD-S	PPDA, B, K(Y), G	Connaught Laboratories, Toronto
			473			
Paul, 1975 ⁵⁸	Kenya	6-17	27	2 TU RT-23	11 reagents	Stanford
			7			SSI, Copenhagen
Ogunmekan, 1977 ⁵⁹	Nigeria	10-15	509	5 TU PPD-S	PPDG, PL, A, F, Y	US Department of Health
			245			
Baily 1980 ³⁴	India	1-14	101 106	3 TU PPD-S [§]	PPD-B	Antigen production laboratory (CDC), Atlanta, GA
Wells, 1982 ⁶⁰	Barbados	3-8	908	5 TU PPD-S	PPD-B	Connaught Laboratories, Toronto
Bahr, 1986 ⁶¹	Lebanon	7-17	1 823	No TST	Leprosin A, Vaccin, Scrofulin	Stanford's method
Frappier-Davignon, 1989 ⁶²	Quebec	15-19	1 047	2 TU RT-23	PPDB, K	SSI, Copenhagen
Ly, 1989 ⁶³	Vietnam	12	153	No TST	15 new tuberculins	Stanford
			155			
Menzies, 1989 ⁶⁴	Montreal	11.6	2 408	5 TU PPD-S	PPD-B	Connaught Laboratories, Toronto
		16.1	983			
Lind, 1991 ⁶⁵	Sweden	8-9	1 368	2 TU RT-23	<i>M. avium</i> RS10, <i>M. scrofulaceum</i> RS95	SSI, Copenhagen
			1 451			
von Reyn, 1993 ⁶⁶	NH	18-65	102	5 TU PPD-S	0.1 ml PPD-RS 10 (<i>M. avium</i>)	Connaught Laboratories, Toronto
	Boston	18-65	104			SSI, Copenhagen
	Finland	18-45	74			
	Trinidad	18-65	102			
	Kenya	18-65	102			
Osman, 1994 ⁶⁷	Saudi Arabia	6-12	34	2 TU RT-23	PPDA, G	SSI, Copenhagen
			38			
Fine, 2001 ⁶⁸	Malawi	20-65	2 623	2 TU RT-23	A, B, G and 12 others	Stanford
			2 886			SSI, Copenhagen
			3 324			
von Reyn, 2001 ⁶⁹	South US	29	284	5 TU PPD-S	0.1 ml MAS 10/2	SSI, Copenhagen
	North US	29	500			US Department of Health
Bierrenbach, 2003 ²⁵	Brazil	11	170	2 TU RT-23	PPD-A, G, F, K	SSI, Copenhagen
			145			

* Northern: any of the following states: CA, CO, CT, DC, ID, IL, IN, IA, KY, ME, MA, MI, MN, MT, NH, NJ, NY, OH, OR, PA, RI, SD, UT, VT, WA, WI, WY.

[†] Central states: DE, KS, MD, MO, NE, NV, NM, NC, ND, OK, TN, VA, WV.

[‡] Southern states: AL, AZ, AR, FL, GA, LA, MS, SC, TX.

[§] For this study, a preliminary study demonstrated that 3TU of the PPD-S used was bioequivalent to 5TU PPD-S. Hence this PPD dose was considered bioequivalent to 5TU PPD-S.³⁴

NTM = non-tuberculous mycobacteria; TST = tuberculin skin test; LTBI = latent tuberculosis infection; PPD-S = studies using commercial PPD standardised to PPD-S; PPD = purified protein derivative; SSI = Statens Serum Institute.

search, 46 were reviewed in depth and 18 studies, summarised in Table 3, met the review inclusion criteria.

Effect of BCG on TST

We examined the size of BCG-associated TST reactions, age when vaccinated, interval between vaccination and TST, and type of tuberculin material. Number of BCG vaccinations received could not be assessed, as this was confounded with age when vaccinated and interval since vaccination. Nor could we analyse the effect of BCG vaccine strain because many different strains were used (Danish—eight studies, Armand-Frappier—four, Pasteur—one, Tice—one, Connaught—one, Moreau—one, two strains—three, many strains—four), or the strain was not specified in eight studies. Age at BCG vaccination was categorised into vaccination in infancy (first year of life) or later. This reflects BCG vaccination policy in many countries where it is given just after birth and/or in primary school.²⁸ Interval was dichotomised into more or less than 10 years, using the average or the midpoint if a range was given.

In each study, we compared the proportion of BCG-vaccinated or non-vaccinated individuals with TST reactions in four categories (0–4, 5–9, 10–14 and ≥ 15 mm), three categories (0–4, 5–9 and ≥ 10 mm), or two categories (0–9 and ≥ 10 mm). For each TST size category, the difference between vaccinated and non-vaccinated was assumed to represent the percentage with false-positive (FP) TST due to BCG (the FP-TST_{BCG}). For each study, the number BCG-vaccinated was multiplied times this percentage to estimate the total number of individuals with FP-TST_{BCG} in that TST size range. These values from all studies were combined in a weighted average FP-TST_{BCG} for each TST size category.

Effect of NTM on TST

Definitions

The following definitions were used to calculate the effect of NTM on TST, and vice versa:

- TST reaction: skin test reaction to antigens (PPD) derived from *Mycobacterium tuberculosis*.
- Positive TST: reaction to PPD of ≥ 10 mm.
- NTM reactions: reactions to antigens derived from NTM.
- Positive NTM: reaction to NTM antigens of ≥ 5 mm.
- TST or NTM cross-reactions: these could be determined only if dual TST was performed simultaneously with PPD and NTM antigens. If the reaction to one antigen was larger than the other, the smaller reaction was considered a cross-reaction.^{56,71,72}
- TST dominant: TST reaction equal to or greater than NTM reaction. In this case, the reaction to the NTM was assumed to be a cross-reaction.
- NTM dominant: reaction to NTM antigen was more than 1 mm larger than the TST reaction (to ensure NTM was truly bigger).^{56,71,72}

- FP-TST_{NTM}: false-positive TST due to NTM. When the TST was 10–14 mm and the dual NTM reaction was larger (dominant), then the TST reaction was considered a cross-reaction from NTM sensitivity.^{56,71,72} The TST was thus considered false-positive.
- Dual mycobacterial infection: if the TST is ≥ 15 mm, the subject is considered to have TB infection (true positive), even if the NTM reaction is larger.^{71,72} These persons are believed to have latent TB infection (with *M. tuberculosis*), and sensitisation to an NTM.^{71,72}

Calculating the effect of NTM on TST reactions

In the 18 studies reviewed, different definitions of a positive NTM test were used. Five studies provided millimetre by millimetre results. We used these to calculate the ratio between reactions of 2, 4 and 6 mm to reactions of 5 mm (Table 4). We used the same studies to estimate a correction factor to account for false-positive NTM reactions due to larger reactions to TST (Table 4). These two correction factors were applied to 12 studies in which dual testing with TST and NTM antigens was performed. We used these to estimate the rate of false-positive TST per 100 individuals with NTM reactions of 5+ mm—the FP-TST_{NTM}. This rate was applied to the prevalence (standardised and corrected, as above) of NTM in 18 surveys to estimate the absolute rate of false-positive TST related to NTM in different regions and countries of the world.

RESULTS

False-positive TST from BCG

Based on 240 203 vaccinees in 24 studies reviewed, BCG vaccination in infancy caused an overall rate of 8.5 false-positive TST reactions (FP-TST_{BCG}) per 100 vaccinees, with a rate of 2.6 FP-TST_{BCG} per 100 vaccinees for reactions of 15+ mm (Table 5). BCG received by 12 728 subjects after the age of 1 year caused 41.8 false-positive TST reactions (10+ mm) per 100 vaccinees; about half of these reactions measured 15+ mm (Table 6). In the six studies that included persons vaccinated at different ages, BCG vaccination at an older age had a much greater effect on TST than BCG in infancy^{4–7} (Figures 1 and 2).

As seen in Table 7, after 10 years (a clinically useful cut-off, although without biological justification), the effect of the BCG received in infancy was virtually nil (1.0 FP-TST_{BCG} per 100 vaccinees). On the other hand, the effect on TST of BCG vaccination after the first year of life seems to persist, although there is significant waning. The distribution of reactions (10–14 mm vs. 15+ mm) is not different in those tested 10+ years after vaccination, compared to those tested sooner.

The prevalence of positive reactions to 5 TU PPD-S, 1 TU RT23 or 2 TU RT23, was similar in subjects who had been BCG vaccinated in infancy (Table 7). Among subjects vaccinated in later childhood, prevalence of

Table 4 NTM size standardisation ratios and correction factor for true TB infection, from five studies with complete data (mm by mm) from dual testing with NTM and *M. tuberculosis* antigens

Author, year	Setting	Participants		NTM antigen	NTM size standardisation ratios				Correction factor for NTM reactions due to true TB infection			
		Age, years range or mean	n		NTM reaction prevalence				Total prevalence of TST reactions		Frequency of non-dominant NTM reactions* when TST is	
					≥2 mm %	≥4 mm %	≥5 mm %	≥6 mm %	≥10 mm %	≥5 mm %	≥10 mm %	≥5 mm %
Bleiker, 1968 ⁵⁴	Netherlands	6–15	3108	A	21.8	10.0	7.5	5.7	1	4	44	25
	France	6–15	2038	A	9.9	8.1	7.7	7.0	10	12	43	37
Brickman, 1974 ⁵⁷	Montreal	4–6	554	A	3	3	3	2	1	2	32	28
			567	B	3	3	3	2				
			473	G	6	5	5	5				
Paul, 1975 ⁵⁸	Kenya	6–17	27	A	n/a	n/a	44	37	14	21	44	41
			7	G			29	29				
Menzies, 1989 ⁶⁴	Montreal	11.6	2408	B	n/a	9	7	7	5	9	35	31
			983	B	n/a	17	14	14				
Lind, 1991 ⁶⁵	Sweden	8–9	1368	A	52.4	37.4	32.3	25.4	1	6	22	27
			1451	G	56.3	42.5	38.2	32.4				
Standardising factors [†]					0.613	0.856	1.000	1.202				
Average correction factor (of TST causing cross-reacting non-dominant NTM reaction)											39	31

* Non-dominant NTM reaction defined as [NTM ≥5 mm] and [NTM ≤TST+1] (see definitions in text).

[†] Weighted average of ratio of [Prevalence at cut-off = 5 mm]/[Prevalence at cut-off = n mm].

NTM = non-tuberculous mycobacteria; TB = tuberculosis; TST = tuberculin skin test.

positive TST was higher in two studies of subjects tested with 2 TU RT23, compared to subjects in 10 studies tested with 5 TU-PPDS. However, test type was confounded with interval: both studies using RT23 involved shorter intervals of 5 and 8 years.

False-positive TST from NTM

As shown in Table 8, based on the 12 studies with 1 169 105 persons who underwent dual TST and NTM testing, 2.0 persons would have a false-positive TST (of 10–14 mm) per 100 persons with NTM reactions of 5+ mm (FP-TST_{NTM}). Using only the five studies of 12 984 persons with detailed data, the absolute rate of FP-TST_{NTM} was 2.7 per 100 NTM-sensitised population. When this higher estimate of FP-TST_{NTM} was multiplied by the prevalence of NTM reactions of 5+ mm in the 18 NTM prevalence surveys reviewed, the absolute prevalence of FP-TST_{NTM} ranged from 0.1% in Montreal or France to a maximum of 2.3% in India (Table 9).

DISCUSSION

The results of this review indicate that the impact of BCG vaccination on TSTs was strongly affected by age when vaccinated and interval since vaccination, but not by type of tuberculin material. Size of reaction was not that helpful in distinguishing BCG-related TST from true infection. False-positive TSTs due to NTM were very uncommon, and thus important only in populations with a low prevalence of true TB infection.

Although the overall estimates of impact of BCG

in infancy and at an older age are based on a large number of studies and very large numbers of vaccinees, the sub-group analyses were limited by smaller numbers of studies and vaccinees. Studies with very large numbers would tend to skew results, given our method of weighting estimates by the size of study populations. However, unweighted estimates of the effect of age when BCG-vaccinated and interval since vaccination were similar to the weighted estimates. We calculated the absolute effect of BCG or NTM on tuberculin reactions independently of the prevalence of TB infection. Such estimates should be applicable and useful for calculating positive predictive value in all BCG vaccinated populations with very different prevalences of true TB infection.

This review demonstrates that age when BCG-vaccinated is a critical determinant of subsequent tuberculin reactions. The finding that BCG in infancy has little effect, particularly 10 years or more after vaccination, means that adolescents or adults who were BCG-vaccinated in infancy with a TST of 10+ mm can be assumed to have a true positive TST. This lack of effect is biologically plausible, as the immune response to BCG given in the first few months of life is much less than the immune response to BCG given after 9 months.⁷³ The prevalence of positive TST has also been correlated with number of BCG scars—a proxy of older age when last vaccinated.^{3,74} BCG in older childhood produces more frequent, more persistent and larger TSTs, making this group of vaccinees the most likely to benefit from the application of new, highly specific IGRA tests. However, it might be anticipated that this group will diminish over time, given

Table 5 Details of calculations of effect on tuberculin reactions of BCG in infancy (subtracting TST in non-vaccinated from TST in vaccinated, and deriving weighted estimates)

Author, year	n tested	TST in BCG				TST in non-vaccinated				Difference in prevalence				Number with FP-TST _{BCG}			
		5-9 mm %	10-14 mm %	15+ mm %	%	5-9 mm %	10-14 mm %	15+ mm %	%	5-9 mm %	10-14 mm %	15+ mm %	%	5-9 mm n	10-14 mm n	15+ mm n	
Eason, 1987 ⁹	1425			2.5				2.2				0.3				4	
Karaliedde, 1987 ¹⁰	522			3.9			4.4					-0.5				-3	
al-Kassimi, 1991 ¹¹	1945			11.5			5.1					6.4				125	
el-Kassimi, 1991 ¹²	283	11.0	18				4.5			1.9	13.5			5	38		
Menzies, 1992 ⁶	1041	7.5	5.0	2.7	9.1	1.1	1.2			6.0	3.9	1.5	62	41	16		
Young, 1992 ¹³	522	3.8	2.2	4.0	2.4	6.0	5.4			1.4	-3.8	-1.4	7	-20	-7		
al-Kassimi, 1993 ¹⁴	2119			12.0			5.6					6.4				136	
Menzies, 1994 ⁷	381			8.1			2.3					5.8				22	
Miret-Cuadras, 1996 ⁵	446	24.0	20.1	9.0	5.4	6.8	5.2			18.6	13.3	3.8	83	59	17		
Bener, 1996 ¹⁵	544	8.6	11.8		7.2	7.5				1.4	4.3		8	23			
Getchell, 1992 ¹⁶	251	19.5	39.9		2.5	42.5				17	-2.6		43	-7			
Liard, 1996 ¹⁷	920	10.0	16.0	9.8	4.0	3.2	1.9			6	12.8	7.9	55	118	73		
Schwartzman, 1996 ¹⁸	76			33.0			18.0				15.0					11	
Jochem, 1997 ¹⁹	11			27.0			23.0				4.0					0.4	
Bosman, 1998 ²⁰	25381	13.8	10.5	7.4	10.7	5.2	5.3			3.1	5.3	2.1	787	1345	533		
Chadha, 2000 ²¹	3165	40.5	21.5	15.2	45.8	17.6	10.3			-5.3	3.9	4.9	-168	123	155		
Chadha, 2001 ²²	5653	27.4	12.9	14.4	27.3	8.4	12.1			0.1	4.5	2.3	6	254	277*		
Tanzania, 2001 ²³	161357	—	19.1	8.3	—	12.5	5.3			—	6.6	3.0	—	10621	4799		
Chadha, 2003 ²⁴	5542	15.0	7.8	6.0	11.5	5.9	7.7			3.5	1.9	-1.7	194	116	-94*		
Bierenbach, 2003 ²⁵	437	23.3	12.6	3.2	10.6	6.2	5.4			12.7	6.4	-2.2	55	28	-10		
Lienhardt, 2003 ²⁶	2314	10.2	20.9	8.6	11.2	21.2	12.1			-1.0	-0.3	-3.5	-23	-7	-81		
Chadha, 2004 ²⁷	24398	24.5	12.2	14.1	18.6	7.0	11.6			5.9	5.2	2.5	1439	1269	610		
Hill, 2004 ²⁸	959	6.3	10.3	28.0	6.0	13.0	27.0			0.3	-2.7	1.0	3	-26	10		
Pai, 2005 ²⁹	511	21.1	18.6	22.7	14.5	17.5	25.0			6.6	1.1	-2.3	34	6	-12		
Total number BCG-vaccinated: studies with TST results in four categories (14 studies)							232646						2590	13918	6139		
Total number BCG-vaccinated: studies with TST results in three categories (16 studies)							72367							20406			
Total number BCG-vaccinated: all studies. TST results in two categories (24 studies)							240203							60			
Mean of effect estimated in each study: four size categories										4.9	4.1	1.2					
Mean of effect estimated in each study: two size categories												4.5					
Average effect - weighted by number of BCG vaccinees in each study: four size categories (14 studies)							232646						3.6	6.0	2.6		
Average effect - weighted by number of BCG vaccinees in each study: 10+ mm only (24 studies)							240203									8.5	

Summary of calculations of weighted averages:

Reactions of 5-9 mm: 2590/72367 (16 studies) = 3.6%.
 Reactions of 10-14 mm: 13918/232646 (14 studies) = 6.0%.
 Reactions of 15+ mm: 6139/232646 (14 studies) = 2.6%.
 In total reactions of 10+ mm: 20406/240203 (24 studies) = 8.5%.
 BCG = bacille Calmette-Guérin; TST = tuberculin skin test; FP = false-positive.

Table 6 Details of calculation of effect on tuberculin reactions of BCG given after the age of 1 year (subtracting TST in non-vaccinated from TST in vaccinated, and deriving weighted estimates)

Author, year	n tested	TST in BCG-vaccinated		TST in non-vaccinated		Difference in prevalence		Number with FP _{BCG older}	
		10–14 mm %	15+ mm %	10–14 mm %	15+ mm %	10–14 mm %	15+ mm %	10–14 mm n	15+ mm n
Abrahams, 1967 ³⁰	53	19.1	1.9	0.9	1.2	18.2	0.7	5	0.4
Abrahams, 1968 ³¹	395	10.3	0.8	0.3	0.3	10	0.5	40	2
Comstock, 1971 ³²	63	11.1	4.8	1.5	0	9.6	4.8	6	3
Horwitz, 1972 ³³	716	15.2	64.8	0.6	0.8	14.6	64	105	458
Baily, 1980 ³⁴	8 702		62.9		20.4		42.5		3 698
Eason, 1987 ⁹	1 395	33	11	9	6	24	5	335	70
Menzies, 1992 ⁶	469	12.8	10.2	1.4	1.6	11.4	8.6	53	40
Menzies, 1994 ⁷	210		26.2		2.3		23.9		50
Ildirim, 1995 ³	470	40.9	30.2	6	5	34.9	25.2	164	118
Schwartzman, 1996 ¹⁸	117		43		18		25		29
Jochem, 1997 ¹⁹	39		46		23		23		9
Kang, 2005 ³⁵	99	24	27	7	10	17	17	17	17
Total	10+ 10–14, 15+	12 728 3 660						5 314 725	708

Summary of calculations of weighted averages:

Total TST reactions attributable to BCG:

Reactions of: 10+ mm (12 studies) = 5314/12 728 = 41.8%.

10–14 mm (8 studies) = 725/3660 = 19.8%.

15+ mm (8 studies) = 708/3660 = 19.4%.

BCG = bacille Calmette-Guérin; TST = tuberculin skin test; FP = false-positive.

Table 7 Modification of effect of BCG vaccination on TST by age of BCG vaccination, interval between BCG and TST, as well as type of TST

Comparison	BCG in infancy			BCG older (after age of 1 year)		
	n subjects (n studies)	Positive TST		n subjects (n studies)	n positive	
		Criteria mm	n (%)		Criteria mm	n (%)
Overall effect from all studies	240 203 (24)	10+	20 406 (8.5)	12 728 (12)	10+	5 314 (41.8)
By interval						
≤10 years	234 464 (16)	10	4 930 (8.7)	3 128 (7)	10	5 123 (43.3)
>10 years	5 739 (8)	10	56 (1.0)	898 (5)	10	191 (21.2)
By TST size	71 289 (13)	10–14	3 297 (4.6)	3 660 (8)	10–14	725 (19.8)
		15+	1 340 (1.9)		15+	708 (19.4)
By interval and TST size						
≤10 years	170 401* (9)	10–14	13 854 (8.1)	3 128* (6)	10–14	649 (20.7)
		15+	6 346 (3.7)		15+	665 (21.3)
>10 years	5 271 (5)	10–14	73 (1.4)	532 (2)	10–14	59 (11.1)
		15+	0 (0)		15+	43 (8.1)
By type of TST						
5TU PPD5	170 401 (13)	10+	15 878 (9.3)	11 913 (10)	10+	4 622 (39.0)*
1TU RT23	39 791 (6)	10+	2 701 (6.8)	—	—	—
2TU RT23	30 011 (5)	10+	2 056 (6.9)	815 (2)	10+	597 (73.3)*

* Of the 10 studies using 5TU PPD5 to test subjects vaccinated at an older age, 5 involved average intervals of ≥10 years between vaccination and TST. On the other hand, both studies using 2TU RT23 involved shorter intervals of 5 or 8 years.

BCG = bacille Calmette-Guérin; TST = tuberculin skin test.

the current World Health Organization recommendations to give BCG only in infancy⁷⁵ as there is no benefit of revaccination in older children.⁷⁶

This review did not consider the effect of BCG vaccine strain because six different strains were used in 16 studies, and multiple or unknown strains in 15. The largest number of studies with a single strain was for BCG-Danish, six of which reported results for vaccination in infancy. The average TST-FP_{BCG} effect was 6.6% (compared to 8.5% overall), and ranged from

17.1% (the second largest effect in all 24 studies) to –1.2% (third smallest). No other comparison could be made, given the very small size of the sub-groups. Other evidence is contradictory regarding BCG strain as a determinant of post-vaccinal tuberculin reactions. In one experimental study,³³ there was minimal inter-strain variation in tuberculin reactions after 5 years. Nevertheless, in one review, substantial differences in post-vaccinal tuberculin reactivity were noted,⁷⁷ but were not associated with vaccine efficacy. Behr and col-




Figure 1 Effect on TST reactions of BCG vaccination in infancy. Dashed line: weighted average effect in studies where the interval from BCG until TST was <10 years. Dotted line: weighted average effect in studies where the interval from BCG until TST was >10 years. Diamonds: point estimates (and SE bars) from individual studies with interval of <10 years. Squares: point estimates from individual studies with interval of ≥ 10 years. FP = false-positive; TST = tuberculin skin test; BCG = bacille Calmette-Guérin; SE = standard error. References for studies: 1: Eason,⁹ 2: Karalliedde,¹⁰ 3: El Kassimi,¹¹ 4: El Kassimi,¹² 5: Menzies,⁶ 6: Young,¹³ 7: El Kassimi,¹⁴ 8: Menzies,⁷ 9: Miret,⁵ 10: Bener,¹⁵ 11: Getchell,¹⁶ 12: Liard,¹⁷ 13: Schwartzman,¹⁸ 14: Jochem,¹⁹ 15: Bosman,²⁰ 16: Chadha,²¹ 17: Chadha,²² 18: Tanzania TB Survey,²³ 19: Chadha,²⁴ 20: Bierrenbach,²⁵ 21: Lienhardt,²⁶ 22: Chadha,²⁷ 23: Hill,²⁸ 24: Pai.²⁹




Figure 2 Effect on TST reactions of BCG vaccination given after the age of 1 year. Dashed line: weighted average effect in studies where the interval from BCG until TST was <10 years. Dotted line: weighted average effect in studies where the interval from BCG until TST was >10 years. Diamonds: point estimates (and SE bars) from individual studies with interval of ≥ 10 years. Squares: point estimates from individual studies with interval of <10 years. FP = false-positive; TST = tuberculin skin test; BCG = bacille Calmette-Guérin; SE = standard error. References for studies: 1: Eason,⁹ 5: Menzies,⁶ 8: Menzies,⁷ 13: Schwartzman,¹⁸ 14: Jochem,¹⁹ 25: Abrahams,³⁰ 26: Abrahams,³¹ 27: Comstock,³² 28: Horwitz,³³ 29: Baily,³⁴ 30: Ildirim,³ 31: Kang.³⁵

Table 8 Using 12 studies with dual testing to estimate the false-positive TST rate per 100 NTM sensitised (FP-TST_{NTM})

Author, year	Setting	Participants		Prevalence of NTM infection		False-positive TST per 100 with NTM dominant (FP TST _{NTM})	
		Age, years range or mean	<i>n</i>	Antigen	Standardised and corrected %	10–11 mm	10–14 mm
Studies providing complete data*							
Bleiker, 1968 ⁵⁴	The Netherlands	6–15	3 108	A	6.4	1.5	4.0
	France	6–15	2 038	A	3.0	4.8	11.3
Brickman, 1974 ⁵⁷	Montreal	4–6	1 594	A/B/G	3	12	12
Paul, 1975 ⁵⁸	Kenya	6–17	34	A/G	24	0	5
Menzies, 1989 ⁶⁴	Montreal	11.6	2 408	B	3	0	1.4
		16.1	983	B	8	7.9	7.9
Lind, 1991 ⁶⁵	Sweden	8–9	2 819	A/G	34.1	0.7	1.1
Cumulative TST-FP/100 NTM from five studies						1.6	2.7
Studies with categorical data*							
Jeanes, 1969 ⁵⁵	Canada	14–22	33 741	B/G	6.2	—	3.1
Edwards, 1973 ⁵⁶	US–North [†]	17–21	573 141	B/G	16	1.0	1.5
	US–Central [‡]	17–21	268 554	B/G	28	0.7	1.3
	US–South [§]	17–21	185 475	B/G	44	0.9	1.3
Baily, 1980 ³⁴	India	1–14	101 106	B	85	2.4	5.7
Wells, 1982 ⁶⁰	Barbados	3–8	908	B	23	0	0
Frappier-Davignon, 1989 ⁶²	Quebec	15–19	1 047	B	3	0	0
von Reyn, 2001 ⁶⁹	US	29	784	A	38	1.6	3.6
Bierrenbach, 2003 ²⁵	Brazil	10.9	315	A/G	35	—	8.2
Cumulative TST-FP/100 NTM from all twelve studies						1.1	2.0

* The first five studies provided mm by mm data for all skin test reactions. The remaining six provided categorical data (i.e., reactions of 5–9, 10–14 mm, etc.).

[†] Northern states include the following: CA, CO, CT, DC, ID, IL, IN, IA, KY, ME, MA, MI, MN, MT, NH, NJ, NY, OH, OR, PA, RI, SD, UT, VT, WA, WI, WY.

[‡] Central states: DE, KS, MD, MO, NE, NV, NM, NC, ND, OK, TN, VA, WV.

[§] Southern states: AL, AZ, AR, FL, GA, LA, MS, SC, TX.

TST = tuberculin skin test; BCG = bacille Calmette-Guérin; FP = false-positive.

leagues noted that vaccine efficacy appeared to wane over successive BCG strain cultures, but that tuberculin reactivity was maintained,⁷⁸ differences that were associated with significant genetic deletions.⁷⁹ The authors speculated that this was due to the selection by vaccine manufacturers of strains that produced tuberculin reactivity. This was done to comply with regulatory authorities in many countries, who required proof of post-vaccinal tuberculin reactivity (which was easy to measure), rather than vaccine efficacy (which was not).

Use of the 5 mm cut-off point to define NTM sensitivity was arbitrary. This definition was adopted because the studies of NTM reviewed used cut-off points of 2–6 mm to define NTM sensitivity. The 5 mm definition was thus used to facilitate comparison of the different studies reviewed, and to compare our results with others. This also allows us to calculate the likelihood of false-positive TST in any setting where the prevalence of NTM sensitivity is known. In reality, only NTM reactions of 12+ mm will cause false-positive TST (with PPD-S or equivalent) of 10+ mm, so it is only the prevalence of such reactions that are of interest. However, use of a definition of NTM reactions of 12+ mm could have caused some confusion, as the resultant estimated prevalence of NTM sensitivity would have been much lower than all published estimates.

This review demonstrates that the absolute impact of NTM is surprisingly low, even in populations with a high prevalence of NTM sensitivity. NTM reactions will therefore be important only if the likelihood of true TB infection is very low. For example, in a young adult from the Southern US, the likelihood that a TST of 10–14 mm indicates TB infection will be below 50%, because the expected prevalence of true TB infection in this population is below 1%. On the other hand, in adults from India, Malawi or Brazil, the likelihood that a TST of the same size indicates TB infection exceeds 95%.

CONCLUSIONS

The effect on TST of BCG received in infancy is minimal, and virtually nil 10 years or more after vaccination. BCG given after the age of 1 year produces more frequent, persistent, and larger TST reactions. NTM is not an important cause of false-positive TST, except in populations with a high prevalence of NTM sensitisation and a very low prevalence of TB infection.

Based on this review it can be predicted that new IGRAs will be most useful in populations who have received BCG vaccination after the age of 1 year. In settings where BCG vaccination was not given, or given only in infancy, the specificities of TST and IGRAs should be similar and the selection of TST or IGRA

Table 9 Estimated absolute prevalence of false-positive TST (of 10–14 mm), due to cross-reactions from NTM in a healthy general population sample

Author, year	Setting	Participants		NTM prevalence*		FP-TST _{NTM} (10–14 mm)	
		Age, years	<i>n</i>	Antigen	Prevalence %	Lower estimate %	Higher estimate %
Bleiker, 1968 ⁵⁴	Netherlands	6–15 (boys)	3 108	A	6.4	0.1	0.2
	France	6–15 (girls)	2 038	A	3.0	0.0	0.1
Brickman, 1974 ⁵⁷	Montreal	4–6	567	B	2	0.0	0.1
			473	G	4	0.1	0.1
Paul, 1975 ⁵⁸	Kenya	6–17	27	A	22	0.4	0.6
			7	G	29	0.6	0.8
Menzies, 1989 ⁶⁴	Montreal	11.6 16.1	2 408	B	3	0.0	0.1
			983	B	8	0.2	0.2
Lind, 1991 ⁶⁵	Sweden	8–9	1 368	A	31	0.6	0.8
			1 451	G	38	0.8	1.0
Edwards, 1973 ⁵⁶	US–North [†]	17–21	573 141	B/G	16	0.3	0.4
	US–Central [‡]	17–21	268 554	B/G	28	0.6	0.8
	US–South [§]	17–21	185 475	B/G	44	0.9	1.2
	US–Florida			B/G	51	1.0	1.4
Ogunmekan, 1977 ⁵⁹	Nigeria	10–15	509	A	33	0.7	0.9
			245	G	34	0.7	0.9
Baily, 1980 ³⁴	India	1–14	101 106	B	86	1.7	2.3
Wells, 1982 ⁶⁰	Barbados	3–8	908	B	23	0.5	0.6
Bahr, 1986 ⁶¹	Lebanon	7–17	1 823	G	3	0.1	0.1
Frappier-Davignon, 1989 ⁶²	Quebec	15–19	1 047	B	3	0.1	0.1
Ly, 1989 ⁶³	Vietnam	12	153	AA	15	0.3	0.4
			155	G	6	0.1	0.2
Osman, 1994 ⁶⁷	Saudi Arabia	6–12	34	A	16	0.3	0.4
			38	G	25	0.5	0.7
Fine, 2001 ⁶⁸	Malawi	20–65	2 623	A	39	0.8	1.0
			2 886	B	58	1.2	1.6
			3 324	G	58	1.2	1.6
Bierrenbach, 2003 ²⁵	Brazil	10.9	170	A	36	0.7	1.0
			145	G	34	0.7	0.9
Jeanes, 1969 ⁵⁵	Canada	14–22	26 158	B	4.9	0.1	0.2
			7 583	G	6.6	0.1	0.2
von Reyn, 1993 ⁶⁶	NH, Boston	18–65	206	A	12	0.2	0.3
	Finland	18–45	74	A	3	0.1	0.1
	Trinidad	18–65	102	A	14	0.3	0.4
	Kenya	18–65	102	A	30	0.6	0.9
von Reyn, 2001 ⁶⁹	South US	29	284	A	46	0.9	1.2
	North US		500	A	33	0.7	0.9

* NTM prevalence now corrected for TST dominant reactions and standardised to 5 mm cut-off point.

[†] Northern states: any of the following states: CA, CO, CT, DC, ID, IL, IN, IA, KY, ME, MA, MI, MN, MT, NH, NJ, NY, OH, OR, PA, RI, SD, UT, VT, WA, WI, WY.

[‡] Central states: DE, KS, MD, MO, NE, NV, NM, NC, ND, OK, TN, VA, WV.

[§] Southern states: AL, AZ, AR, FL, GA, LA, MS, SC, TX.

TST = tuberculin skin test; NTM = non-tuberculous mycobacteria; FP = false-positive.

will depend on other considerations such as cost, feasibility and acceptability.

Acknowledgements

The authors thank C Michaud for tireless work on revisions, and L Zolpy for assistance in review of the literature. The authors also thank Drs V Chadha, P Hill and C Lienhardt for sending additional data needed for this analysis.

References

- Pai M, Riley L W, Colford J M Jr. Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review. *Lancet Infect Dis* 2004; 4: 761–776.
- Menzies D. The tuberculin skin test. In: Reichman L, Hershfield E, eds. *Tuberculosis, a comprehensive international approach*. New York, NY, USA: Marcel Dekker, 2000.
- Ildirim I, Hacimustafaoglu M, Ediz B. Correlation of tuberculin induration with the number of Bacillus Calmette-Guerin vaccines. *Pediatr Infect Dis J* 1995; 14: 1060–1063.
- Margus J H, Khassis Y. The tuberculin sensitivity in BCG vaccinated infants and children in Israel. *Acta Tuberc Pneumonol Scand* 1965; 46: 113–122.
- Miret-Cuadras P, Pina-Gutierrez J M, Juncosa S. Tuberculin reactivity in Bacillus Calmette-Guerin vaccinated subjects. *Tubercle Lung Dis* 1996; 77: 52–58.
- Menzies R I, Vissandjee B. Effect of Bacille Calmette-Guerin vaccination on tuberculin reactivity. *Am Rev Respir Dis* 1992; 145: 621–625.
- Menzies R I, Vissandjee B, Rocher I, St Germain Y. The booster

- effect in two-step tuberculin testing among young adults in Montreal. *Ann Intern Med* 1994; 120: 190–198.
- 8 Wang L, Turner M O, Elwood R K, Schulzer M, FitzGerald J M. A meta-analysis of the effect of Bacille Calmette Guerin vaccination on tuberculin skin test measurements. *Thorax* 2002; 57: 804–809.
 - 9 Eason R J. Tuberculin sensitivity. *Ann Trop Paediatr* 1987; 7: 87–90.
 - 10 Karalliedde S, Katugha L P, Urugoda C G. The tuberculin response of Sri Lankan children after BCG vaccination at birth. *Tubercle* 1987; 68: 33–38.
 - 11 al-Kassimi F A, Abdullah A K, al-Orainey I O, et al. The significance of positive Mantoux reactions in BCG-vaccinated children. *Tubercle* 1991; 72: 101–104.
 - 12 al-Kassimi F A, Abdullah A K, al-Orainey I O, Lambourne A, Bener A B, al-Hajjaj M S. Tuberculin survey in the Eastern Province of Saudi Arabia. *Respir Med* 1991; 85: 111–116.
 - 13 Young T K, Mirdad S. Determinants of tuberculin sensitivity in a child population covered by mass BCG vaccination. *Tubercle Lung Dis* 1992; 73: 94–100.
 - 14 el-Kassimi F A, Abdullah A K, al-Hajjaj M S, al-Orainey I O, Bamgboye E A, Chowdhury M N. Nationwide community survey of tuberculosis epidemiology in Saudi Arabia. *Tubercle Lung Dis* 1993; 74: 254–260.
 - 15 Bener A, Uduman S, Bin-Othman S A. Factors associated with tuberculin reactivity among children in United Arab Emirates. *Respir Med* 1996; 90: 89–94.
 - 16 Getchell W S, Davis C E, Gilman J, Urueta G, Ruiz-Huidobro E, Gilman R H. Basic epidemiology of tuberculosis in Peru: a prevalence study of tuberculin sensitivity in a Pueblo joven. *Am J Trop Med Hyg* 1992; 47: 721–729.
 - 17 Liard R, Tazir M, Boulahbal F, Perdrizet S. Use of two methods of analysis to estimate the annual rate of tuberculosis infection in Southern Algeria. *Tubercle Lung Dis* 1996; 77: 207–214.
 - 18 Schwartzman K, Loo V, Pasztor J, Menzies D. Tuberculosis infection among health care workers in Montreal. *Am J Respir Crit Care Med* 1996; 154: 1006–1012.
 - 19 Jochem K, Tannenbaum T N, Menzies D. Prevalence of tuberculin skin test reactions among prison workers. *Can J Public Health* 1997; 88: 202–206.
 - 20 Bosman M C, Swai O B, Kwamanga D O, Agwanda R, Idukita G, Misljenovic O. National tuberculin survey of Kenya, 1986–1990. *Int J Tuberc Lung Dis* 1998; 2: 272–280.
 - 21 Chadha V K, Jagannath P S, Suryanarayana H V. Tuberculin sensitivity in BCG vaccinated children and its implication for ARI estimation. *Indian J Tuberc* 2000; 47: 139–146.
 - 22 Chadha V K, Jagannatha P S, Shashidhar Savanur J. Annual risk of tuberculosis infection in Bangalore city. *Indian J Tuberc* 2001; 48: 63–71.
 - 23 Tanzania Tuberculin Survey Collaboration. Tuberculosis control in the era of the HIV epidemic: risk of tuberculosis infection in Tanzania, 1983–1998. *Int J Tuberc Lung Dis* 2001; 5: 103–112.
 - 24 Chadha V K, Banerjee A, Ibrahim M, Jaganatha P S, Kumar P. Annual risk of tuberculous infection in Khammam, a tribal district of Andhra Pradesh. *J Commun Dis* 2003; 35: 198–205.
 - 25 Bierrenbach A L, Floyd S, Cunha S C, et al. A comparison of dual skin test with mycobacterial antigens and tuberculin skin test alone in estimating prevalence of *Mycobacterium tuberculosis* infection from population surveys. *Int J Tuberc Lung Dis* 2003; 7: 312–319.
 - 26 Lienhardt C, Fielding K, Sillah J, et al. Risk factors for tuberculosis infection in sub-Saharan Africa: a contact study in The Gambia. *Am J Respir Crit Care Med* 2003; 168: 448–455.
 - 27 Chadha V K, Jagannatha P S, Kumar P. Can BCG-vaccinated children be included in tuberculin surveys to estimate the annual risk of tuberculous infection in India? *Int J Tuberc Lung Dis* 2004; 8: 1437–1442.
 - 28 Hill P C, Brookes R H, Fox A, et al. Large-scale evaluation of enzyme-linked immunospot assay and skin test for diagnosis of *Mycobacterium tuberculosis* infection against a gradient of exposure in The Gambia. *Clin Infect Dis* 2004; 38: 966–973.
 - 29 Pai M, Gokhale K, Joshi R, et al. *Mycobacterium tuberculosis* infection in health care workers in rural India: comparison of a whole-blood, interferon- γ assay with tuberculin skin testing. *JAMA* 2005; 293: 2746–2755.
 - 30 Abrahams E W, Harland R D. Sensitivity to avian and human PPD in Brisbane school children. *Tubercle* 1967; 48: 79–94.
 - 31 Abrahams E W, Harland R D. Studies with the purified protein derivative of human and avian tuberculins in South Queensland. *Tubercle* 1968; 49: 192–209.
 - 32 Comstock G W, Edwards L B, Nabangwang H. Tuberculin sensitivity eight to fifteen years after BCG vaccination. *Am Rev Respir Dis* 1971; 103: 572–575.
 - 33 Horwitz O, Bunch-Christensen K. Correlation between tuberculin sensitivity after 2 months and 5 years among BCG vaccinated subjects. *Bull World Health Organ* 1972; 47: 49–58.
 - 34 Baily G V J, Narain R, Mayurnath S, Vallishayee S R S, Guld J. Tuberculosis prevention trial, Madras. *Indian J Med Res* 1980; 72 (Suppl): 1–74.
 - 35 Kang Y A, Lee H W, Yoon H I, et al. Discrepancy between the tuberculin skin test and the whole-blood interferon gamma assay for the diagnosis of latent tuberculosis infection in an intermediate tuberculosis-burden country. *JAMA* 2005; 293: 2756–2761.
 - 36 Ballew K A, Becker D M. Tuberculosis screening in adults who have received bacille Calmette-Guerin vaccine. *South Med J* 1995; 88: 1025–1030.
 - 37 Nelson M E, Fingar A R. Tuberculosis screening and prevention for foreign-born students: eight years experience at Ohio University. *Am J Prev Med* 1995; 11 (Suppl 3): 48–54.
 - 38 Rosenberg T, Manfreda J, Hershfield E S. Two-step tuberculin testing in staff and residents of a nursing home. *Am Rev Respir Dis* 1993; 148: 1537–1540.
 - 39 Cauthen G M, Snider D E, Onorato I M. Boosting of tuberculin sensitivity among Southeast Asian refugees. *Am J Respir Crit Care Med* 1994; 149: 1597–1600.
 - 40 Scholten J N, Fujiwara P I, Frieden T R. Prevalence and factors associated with tuberculosis infection among new school entrants, New York City, 1991–1993. *Int J Tuberc Lung Dis* 1999; 3: 31–41.
 - 41 Larsson L O, Magnusson M, Skoogh E-E, Lind A. Sensitivity to sensitins and tuberculin in Swedish children. IV. The influence of BCG-vaccination. *Eur Respir J* 1992; 5: 584–586.
 - 42 Tissot F, Zanetti G, Francioli P, Zellweger J P, Zysset F. Influence of bacille Calmette-Guerin vaccination on size of tuberculin skin test reaction: to what size? *Clin Infect Dis* 2005; 40: 211–217.
 - 43 McKay A, Kraut A, Murdzak C, Yassi A. Determinants of tuberculin reactivity among health care workers: Interpretation of positivity following BCG vaccination. *Can J Infect Dis* 1999; 10: 134–139.
 - 44 Azbite M. Tuberculin survey in Ethiopia. *Kekkaku* 1992; 67: 539–544.
 - 45 Spinaci S, De Virgilio G, Bugiani M, Linari D, Bertolaso G, Elo O. Tuberculin survey among Afghan refugee children. Tuberculosis control programme among Afghan refugees in North West Frontier Province (NWFP) Pakistan. *Tubercle* 1989; 70: 83–92.
 - 46 Borgdorff M W, Borgdorff P J, Trommel J M. A tuberculin survey in the Buhera district. *Cent Afr J Med* 1985; 31: 215–219.
 - 47 Doherty T M, Demissie A, Menzies D, Andersen P, Rook G, Zumla A. Effect of sample handling on analysis of cytokine responses to *Mycobacterium tuberculosis* in clinical samples using ELISA, ELISPOT and quantitative PCR. *J Immunol Methods* 2005; 298: 129–141.
 - 48 Joncas J H, Robitaille R, Gauthier T. Interpretation of the PPD skin test in BCG-vaccinated children. *Can Med Assoc J* 1975; 113: 127–128.
 - 49 Chadha V K, Krishna Murthy M S, Shashidhara A N, Jagan-

- nath P S, Magesh V. Estimation of annual risk of tuberculosis infection among BCG vaccinated children. *Indian J Tuberc* 1999; 46: 105–112.
- 50 Lifschitz M. The value of the tuberculin skin test as a screening test for tuberculosis among BCG-vaccinated children. *Pediatrics* 1972; 36: 624–627.
- 51 Pai M, Kalantri S, Menzies D. Discordance between tuberculin skin test and interferon-gamma assays. *Int J Tuberc Lung Dis* 2006; 10: 942.
- 52 Johnson H, Lee B, Doherty E, Kelly E, McDonnell T. Tuberculin sensitivity and the BCG scar in tuberculosis contacts. *Tubercle Lung Dis* 1995; 76: 122–125.
- 53 Sepulveda R L, Ferrer X, Latrach C, Sorensen R U. The influence of Calmette-Guérin Bacillus immunization on the booster effect of tuberculin testing in healthy young adults. *Am Rev Resp Dis* 1990; 142: 24–28.
- 54 Bleiker M A. An investigation into specific and non-specific tuberculin sensitivity in schoolchildren in eighteen countries. *Bull Int Union Tuberc* 1968; 41: 265–274.
- 55 Jeanes C W L, Davies J W, McKinnon N E. Sensitivity to 'atypical' acid-fast mycobacteria in Canada. *CMAJ* 1969; 100: 1–8.
- 56 Edwards L B, Acquaviva F A, Livesay V T. Identification of tuberculous infected: dual tests and density of reaction. *Am Rev Respir Dis* 1973; 108: 1334–1339.
- 57 Brickman H F, Beaudry P H. Prevalence of mycobacterial sensitivity in Montreal children. *CMAJ* 1974; 110: 640–644.
- 58 Paul R C, Stanford J L, Misljenovic O, Lefering J. Multiple skin testing of Kenyan schoolchildren with a series of new tuberculins. *J Hyg Camb* 1975; 75: 303–313.
- 59 Ogunmekan D A. The extent and importance of sensitization by opportunist mycobacteria in Lagos, Nigeria. *Tubercle* 1977; 58: 201–205.
- 60 Wells A V, Rao K R. Dual intradermal testing of Barbadian children with tuberculin and Battey bacillus antigen. *West Indian Med J* 1982; 31: 198–204.
- 61 Bahr G M, Stanford J L, Rook G A, Rees R J, Frayha G J, Abdelnoor A M. Skin sensitization to mycobacteria amongst school children prior to a study of BCG vaccination in North Lebanon. *Tubercle* 1986; 67: 197–203.
- 62 Frappier-Davignon L, Fortin R, Desy M. Sensitivity to 'atypical' mycobacteria in high school children in two community health departments. *Can J Public Health* 1989; 80: 335–338.
- 63 Ly H M, Trach D D, Long H T, et al. Skin test responsiveness to a series of new tuberculins of children living in three Vietnamese cities. *Tubercle* 1989; 70: 27–36.
- 64 Menzies R I. The determinants of the prevalence of tuberculous infection among Montreal schoolchildren, Thesis for MSc in Epidemiology and Biostatistics. Montreal, Canada: McGill University, 1989.
- 65 Lind A, Larsson O, Bentzon M W, et al. Sensitivity to sensitins and tuberculin in Swedish children. *Tubercle* 1991; 72: 29–36.
- 66 von Reyn C F, Barber T W, Arbeit R D, et al. Evidence of previous infection with *Mycobacterium avium-Mycobacterium intracellulare* complex among healthy subjects: an international study of dominant mycobacterial skin test reactions. *J Infect Dis* 1993; 168: 1553–1558.
- 67 Osman A A, Hakim J G, Luneborg-Nielsen M, et al. Comparative skin testing with PPD tuberculin, *Mycobacterium avium* and *M. scrofulaceum* sensitin in schoolchildren in Saudi Arabia. *Tubercle Lung Dis* 1994; 75: 38–43.
- 68 Fine P E, Floyd S, Stanford J L, et al. Environmental mycobacteria in northern Malawi: implications for the epidemiology of tuberculosis and leprosy. *Epidemiol Infect* 2001; 126: 379–387.
- 69 von Reyn C F, Horsburgh C R, Olivier K N, et al. Skin test reactions to *Mycobacterium tuberculosis* purified protein derivative and *Mycobacterium avium* sensitin among health care workers and medical students in the United States. *Int J Tuberc Lung Dis* 2001; 5: 1122–1128.
- 70 World Health Organization. Global BCG vaccination coverage 2000–2005. Geneva, Switzerland: WHO, 2005. http://www.who.int/immunization_monitoring/en/globalsummary/timeseries/tscoveragebcg.htm Accessed December 2005.
- 71 Palmer C E, Edwards L B, Hopwood L, Edwards P Q. Experimental and epidemiologic basis for the interpretation of tuberculin sensitivity. *J Pediatr* 1959; 55: 413–428.
- 72 Palmer C E, Edwards L B. Identifying the tuberculous infected. The dual-test technique. *JAMA* 1968; 205: 167–169.
- 73 Pabst H F, Kreth H W. Ontogeny of the immune response as a basis of childhood disease. *J Pediatr* 1980; 97: 519–534.
- 74 Sepulveda R L, Heiba I M, King A, Gonzalez B, Elston R C, Sorensen R U. Evaluation of tuberculin reactivity in BCG-immunized siblings. *Am J Respir Crit Care Med* 1994; 149: 620–624.
- 75 World Health Organization. Global Tuberculosis Programme and Global Programme on Vaccines. Statement on BCG revaccination for the prevention of tuberculosis. *Weekly Epidemiol Rec* 1995; 70: 229–236.
- 76 Rodrigues L C, Pereira S M, Cunha S S, et al. Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: the BCG-REVAC cluster-randomised trial. *Lancet* 2005; 366: 1290–1295.
- 77 Comstock G W. Identification of an effective vaccine against tuberculosis. *Am Rev Respir Dis* 1988; 138: 479–480.
- 78 Behr M A, Small P M. Has BCG attenuated to impotence? *Nature* 1997; 389: 133–134.
- 79 Behr M A, Wilson M A, Gill W P, et al. Comparative genomics of BCG vaccines by whole-genome DNA microarray. *Science* 1999; 284: 1520–1523.

R É S U M É

CONTEXTE : Malgré certains inconvénients, le test cutané tuberculinique (TST) reste largement utilisé. Les avantages importants de ce test sont son faible coût, sa simplicité et son interprétation basée sur des publications abondantes dans la littérature. Toutefois, la spécificité du TST est réduite par la vaccination au bacille de Calmette-Guérin (BCG) et par l'exposition à des mycobactéries non-tuberculeuses (NTM).

MÉTHODES : Pour estimer la spécificité du TST, nous avons fait une revue de la littérature publiée depuis 1966 en ce qui concerne les effets de la vaccination BCG et ceux de l'infection à mycobactéries non-tuberculeuses sur le TST. Les études sélectionnées ont comporté des

sujets sains dont le statut vaccinal BCG était documenté, y compris l'âge à la vaccination ; pour les études sur les effets des NTM, on a utilisé des antigènes NTM standardisés chez les sujets sains.

RÉSULTATS : Dans 24 études impliquant 240 203 sujets vaccinés au BCG dans la prime enfance, au total 20 406 (8,5%) avaient un TST ≥ 10 mm attribuable au BCG, mais 56 seulement parmi 5639 (1%) avaient un TST positif s'ils avaient été testés ≥ 10 ans après le BCG. Dans 12 études concernant 12 728 sujets vaccinés après leur premier anniversaire, au total 5314 (41,8%) avaient des TST faussement positifs de ≥ 10 mm et 191 sur 898 (21,2%) après 10 ans. Le type de TST ne modifie pas ces résultats.

tats. Dans 18 études impliquant 1 169 105 sujets, la prévalence absolue des TST faussement positifs provenant d'une réactivité croisée aux NTM varie de 0,1% à 2,3% selon les régions.

CONCLUSIONS : L'effet sur le TST du BCG appliqué dans la prime enfance est minimal, spécialement ≥ 10 ans après la vaccination. Le BCG reçu après la prime en-

fance produit des réactions du TST plus fréquentes, plus persistantes et plus importantes. Les NTM ne sont pas une cause cliniquement importante de TST faussement positif sauf dans les populations où la prévalence de la sensibilisation aux NTM est élevée et où la prévalence de l'infection tuberculeuse est très faible.

RESUMEN

MARCO DE REFERENCIA : Pese a algunos inconvenientes, la prueba cutánea de la tuberculina (TST) se sigue utilizando en forma generalizada. Entre sus ventajas se cuentan el bajo costo, la sencillez y la interpretación respaldada por una base considerable de artículos publicados. Sin embargo, la vacunación bacille Calmette-Guérin (BCG) y la exposición a las micobacterias atípicas (NTM) reducen la especificidad de la reacción a la TST.

MÉTODOS : Con el fin de estimar la especificidad de la TST se analizaron los artículos publicados a partir de 1966, referentes a las consecuencias de la vacuna con BCG y de la infección por NTM sobre la respuesta a la TST. Los estudios escogidos incluyeron individuos sanos con situación confirmada de su vacunación BCG, incluida la edad a la vacunación. En los estudios sobre las NTM se aplicaron antígenos normalizados en individuos sanos.

RESULTADOS : En 24 estudios que incluyeron 240 203 individuos vacunados con el BCG durante el primer año de vida, un total de 20 406 (8,5%) tuvo una reacción TST de ≥ 10 mm atribuible al BCG, pero sólo en 56 de 5639 (1%) la reacción fue positiva cuando se practicó

con un intervalo de ≥ 10 años después de la vacunación. En 12 estudios de 12 728 individuos vacunados después del primer año de edad, un total de 5314 (41,8%) tuvo una reacción TST falsamente positiva de ≥ 10 mm y 191 de 898 (21,2%) con un intervalo de > 10 años. El tipo de TST no modificó estos resultados. En 18 estudios que comprendieron 1 169 105 individuos, la prevalencia absoluta de una reacción TST positiva falsa por reacción cruzada con NTM osciló entre 0,1% y 2,3% en diferentes regiones.

CONCLUSIONES : La repercusión de la BCG recibida en la primera infancia sobre el resultado de la TST es mínima, en particular ≥ 10 años después de la vacunación. El BCG recibido después del primer año de vida, produce con mayor frecuencia reacciones TST positivas, más persistentes y de mayor magnitud. Las NTM no constituyen una causa importante de reacciones positivas falsas, excepto en poblaciones con una alta prevalencia de sensibilización a las mismas y muy baja prevalencia de infección tuberculosa.
